Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
76-90 of 4234 results
NewLink Genetics announces clinical collaboration to assess IO-based combination therapies in pancreatic cancer
NewLink Genetics announced that it has entered into a clinical collaboration agreement with AstraZeneca to evaluate the combination of indoximod, NewLink Genetics’ small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca’s anti-PD-L1 monoclonal antibody, along with standard of care chemotherapy for patients with metastatic pancreatic cancer.
Contract Research & Services > Clinical Trials > News
Pfizer spins off new company with four rare disease therapies
By PBR Staff Writer
US pharma giant Pfizer has spun off four investigational drugs into a new medicines company, dubbed SpringWorks Therapeutics.
Contract Research & Services > Clinical Trials > News
Eleven Biotherapeutics completes Vicinium manufacturing for ongoing clinical trials in non-muscle invasive bladder cancer
Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.
Contract Research & Services > Clinical Trials > News
AbbVie, Bristol-Myers to evaluate ABBV-399/Opdivo regimen in advanced solid tumors
By PBR Staff Writer
AbbVie will evaluate its investigational antibody drug conjugate, ABBV-399 (telisotuzumab vedotin), in combination with Bristol-Myers Squibb’s immunotheraphy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Versartis’ phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
Versartis, an endocrine-focused biopharmaceutical firm that is developing somavaratan, a novel,aong-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that the Velocity Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (GHD) did not meet its primary endpoint of non-inferiority.
Contract Research & Services > Clinical Trials > News
Cavion recruits first patient in multi-center phase 2 clinical trial in Essential Tremor
Cavion announced that the first patient has been enrolled in its new T-CALM Study (Tremor Cav3 Modulation Study), a Phase 2 clinical trial using the company’s T-type calcium channel modulator CX-8998 for patients with Essential Tremor (ET).
Contract Research & Services > Clinical Trials > News
Roche says Venetoclax combination improves PFS in phase III CLL trial
By PBR Staff Writer
Roche has reported that its cancer drug Venclexta/Venclyxto (venetoclax), developed jointly with AbbVie, has succeeded in a phase 3 study in chronic lymphocytic leukaemia (CLL) patients by meeting its primary endpoint.
Contract Research & Services > Clinical Trials > News
Bydureon EXSCEL trial shows favorable cardiovascular safety profile in patients with type-2 diabetes
AstraZeneca has announced full results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type-2 diabetes (T2D) at a wide range of CV risk.
Contract Research & Services > Clinical Trials > News
Vanda's tradipitant improves itch and disease severity in patients with atopic dermatitis
Vanda Pharmaceuticals announced results from an eight-week randomized phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis.
Contract Research & Services > Clinical Trials > News
Amicus Therapeutics’ skin disorder drug SD-101 fails in phase 3 trial
By PBR Staff Writer
Amicus Therapeutics’ skin disorder drug SD-101 has failed to meet the primary endpoints and secondary endpoints in a phase 3 Essence clinical study.
Contract Research & Services > Clinical Trials > News
Onxeo’s liver cancer drug Livatag fails in phase 3 trial
By PBR Staff Writer
French biotechnology company Onxeo has announced that its liver cancer drug Livatag (doxorubicine Transdrug) failed to meet the primary endpoint in a phase 3 trial in adult patients with unresectable hepatocellular carcinoma (HCC).
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Imfinzi lung cancer drug shows significant effect in PACIFIC trial
AstraZeneca and MedImmune have presented the full PFS data from a planned interim analysis of the phase III PACIFIC trial.
Contract Research & Services > Clinical Trials > News
IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results
IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Contract Research & Services > Clinical Trials > News
Teva’s migraine drug fremanezumab succeeds in phase 3 studies
By PBR Staff Writer
Teva Pharmaceutical has reported that its migraine drug fremanezumab had succeeded in its phase 3 HALO studies by meeting all its 25 primary and secondary endpoints.
Contract Research & Services > Clinical Trials > News
Kura Oncology reports positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer
Kura Oncology has announced positive topline results from a phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).
Contract Research & Services > Clinical Trials > News
76-90 of 4234 results